Skip to main content
SpringerLink
Log in

Application of Viral Vectors to Motor Neuron Disorders

  • Protocol
  • First Online:
Viral Vector Approaches in Neurobiology and Brain Diseases

Part of the book series: Neuromethods ((NM,volume 82))

  • 1326 Accesses

Abstract

Motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) are characterized by the progressive loss of motor neurons in the spinal cord and primary motor cortex. Subsequent paralysis of skeletal muscles leads to variable degrees of motor impairment and is inevitably fatal in ALS and type I SMA. A genetic cause has been defined for some of these conditions including SMA. Therefore, motor neuron disorders could become prime targets for gene therapy provided efficient tools can be designed to specifically target widely distributed motor neurons. Here, the application of viral vectors with a neuronal tropism is reviewed in the context of gene delivery to spinal lower motor neurons. The preparation of adeno-associated vector suspensions for motor neuron infection is described. Finally, we emphasize the use of intramuscular and intracerebroventricular delivery of adeno-associated vectors for the specific targeting of motor neurons.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ (2011) Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol 7:616–630

    Article  PubMed  CAS  Google Scholar 

  2. Wee CD, Kong L, Sumner CJ (2010) The genetics of spinal muscular atrophies. Curr Opin Neurol 23:450–458

    Article  PubMed  CAS  Google Scholar 

  3. Van Den Bosch L (2011) Genetic rodent models of amyotrophic lateral sclerosis. J Biomed Biotechnol 2011:348765

    Article  Google Scholar 

  4. Pun S, Santos AF, Saxena S, Xu L, Caroni P (2006) Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat Neurosci 9:408–419

    Article  PubMed  CAS  Google Scholar 

  5. Boillee S, Vande Velde C, Cleveland DW (2006) ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 52:39–59

    Article  PubMed  CAS  Google Scholar 

  6. Ilieva H, Polymenidou M, Cleveland DW (2009) Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol 187:761–772

    Article  PubMed  CAS  Google Scholar 

  7. Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW (2006) Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312:1389–1392

    Article  PubMed  CAS  Google Scholar 

  8. Clement AM, Nguyen MD, Roberts EA, Garcia ML, Boillee S, Rule M, McMahon AP, Doucette W, Siwek D, Ferrante RJ, Brown RH Jr, Julien JP, Goldstein LS, Cleveland DW (2003) Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 302:113–117

    Article  PubMed  CAS  Google Scholar 

  9. Lobsiger CS, Cleveland DW (2007) Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci 10:1355–1360

    Article  PubMed  CAS  Google Scholar 

  10. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, Takahashi R, Misawa H, Cleveland DW (2008) Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 11:251–253

    Article  PubMed  CAS  Google Scholar 

  11. Boillee S, Cleveland DW (2004) Gene therapy for ALS delivers. Trends Neurosci 27:235–238

    Article  PubMed  CAS  Google Scholar 

  12. Hester ME, Foust KD, Kaspar RW, Kaspar BK (2009) AAV as a gene transfer vector for the treatment of neurological disorders: novel treatment thoughts for ALS. Curr Gene Ther 9:428–433

    Article  PubMed  CAS  Google Scholar 

  13. Henriques A, Pitzer C, Dittgen T, Klugmann M, Dupuis L, Schneider A (2011) CNS-targeted viral delivery of G-CSF in an animal model for ALS: improved efficacy and preservation of the neuromuscular unit. Mol Ther 19:284–292

    Article  PubMed  CAS  Google Scholar 

  14. Franz CK, Federici T, Yang J, Backus C, Oh SS, Teng Q, Carlton E, Bishop KM, Gasmi M, Bartus RT, Feldman EL, Boulis NM (2009) Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS. Neurobiol Dis 33:473–481

    Article  PubMed  CAS  Google Scholar 

  15. Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH (2003) Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301:839–842

    Article  PubMed  CAS  Google Scholar 

  16. Lepore AC, Haenggeli C, Gasmi M, Bishop KM, Bartus RT, Maragakis NJ, Rothstein JD (2007) Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Res 1185:256–265

    Article  PubMed  CAS  Google Scholar 

  17. Azzouz M, Hottinger A, Paterna JC, Zurn AD, Aebischer P, Bueler H (2000) Increased motoneuron survival and improved neuromuscular function in transgenic ALS mice after intraspinal injection of an adeno-associated virus encoding Bcl-2. Hum Mol Genet 9: 803–811

    Article  PubMed  CAS  Google Scholar 

  18. Ralph GS, Radcliffe PA, Day DM, Carthy JM, Leroux MA, Lee DC, Wong LF, Bilsland LG, Greensmith L, Kingsman SM, Mitrophanous KA, Mazarakis ND, Azzouz M (2005) Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 11: 429–433

    Article  PubMed  CAS  Google Scholar 

  19. Raoul C, Abbas-Terki T, Bensadoun JC, Guillot S, Haase G, Szulc J, Henderson CE, Aebischer P (2005) Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 11:423–428

    Article  PubMed  CAS  Google Scholar 

  20. Burghes AH, Beattie CE (2009) Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat Rev Neurosci 10:597–609

    Article  PubMed  CAS  Google Scholar 

  21. Passini MA, Cheng SH (2011) Prospects for the gene therapy of spinal muscular atrophy. Trends Mol Med 17:259–265

    Article  PubMed  CAS  Google Scholar 

  22. Le TT, Pham LT, Butchbach ME, Zhang HL, Monani UR, Coovert DD, Gavrilina TO, Xing L, Bassell GJ, Burghes AH (2005) SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet 14:845–857

    Article  PubMed  CAS  Google Scholar 

  23. Foust KD, Wang X, McGovern VL, Braun L, Bevan AK, Haidet AM, Le TT, Morales PR, Rich MM, Burghes AH, Kaspar BK (2010) Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 28:271–274

    Article  PubMed  CAS  Google Scholar 

  24. Passini MA, Bu J, Roskelley EM, Richards AM, Sardi SP, O’Riordan CR, Klinger KW, Shihabuddin LS, Cheng SH (2010) CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest 120:1253–1264

    Article  PubMed  CAS  Google Scholar 

  25. Dominguez E, Marais T, Chatauret N, Benkhelifa-Ziyyat S, Duque S, Ravassard P, Carcenac R, Astord S, Pereira de Moura A, Voit T, Barkats M (2011) Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet 20:681–693

    Article  PubMed  CAS  Google Scholar 

  26. Valori CF, Ning K, Wyles M, Mead RJ, Grierson AJ, Shaw PJ, Azzouz M (2010) Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med 2:35ra42

    Article  PubMed  Google Scholar 

  27. Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, Kingsman SM, Carmeliet P, Mazarakis ND (2004) VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429:413–417

    Article  PubMed  CAS  Google Scholar 

  28. Mentis GZ, Gravell M, Hamilton R, Shneider NA, O’Donovan MJ, Schubert M (2006) Transduction of motor neurons and muscle fibers by intramuscular injection of HIV-1-based vectors pseudotyped with select rabies virus glycoproteins. J Neurosci Methods 157:208–217

    Article  PubMed  CAS  Google Scholar 

  29. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27:59–65

    Article  PubMed  CAS  Google Scholar 

  30. Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, Douar AM, Fyfe J, Moullier P, Colle MA, Barkats M (2009) Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 17:1187–1196

    Article  PubMed  CAS  Google Scholar 

  31. Miyake N, Miyake K, Yamamoto M, Hirai Y, Shimada T (2011) Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors. Brain Res 1389:19–26

    Article  PubMed  CAS  Google Scholar 

  32. Towne C, Schneider BL, Kieran D, Redmond DE Jr, Aebischer P (2010) Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6. Gene Ther 17:141–146

    Article  PubMed  CAS  Google Scholar 

  33. Towne C, Setola V, Schneider BL, Aebischer P (2011) Neuroprotection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic benefit in fALS mice. Mol Ther 19:274–283

    Article  PubMed  CAS  Google Scholar 

  34. Bevan AK, Duque S, Foust KD, Morales PR, Braun L, Schmelzer L, Chan CM, McCrate M, Chicoine LG, Coley BD, Porensky PN, Kolb SJ, Mendell JR, Burghes AH, Kaspar BK (2011) Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther 19:1971–1980

    Article  PubMed  CAS  Google Scholar 

  35. Wu R, Wang H, Xia X, Zhou H, Liu C, Castro M, Xu Z (2009) Nerve injection of viral vectors efficiently transfers transgenes into motor neurons and delivers RNAi therapy against ALS. Antioxid Redox Signal 11:1523–1534

    Article  PubMed  CAS  Google Scholar 

  36. Bru T, Salinas S, Kremer EJ (2010) An update on canine adenovirus type 2 and its vectors. Viruses 2:2134–2153

    Article  PubMed  CAS  Google Scholar 

  37. Salinas S, Bilsland LG, Henaff D, Weston AE, Keriel A, Schiavo G, Kremer EJ (2009) CAR-associated vesicular transport of an adenovirus in motor neuron axons. PLoS Pathog 5:e1000442

    Article  PubMed  Google Scholar 

  38. Hollis ER 2nd, Kadoya K, Hirsch M, Samulski RJ, Tuszynski MH (2008) Efficient retrograde neuronal transduction utilizing self-complementary AAV1. Mol Ther 16:296–301

    Article  PubMed  CAS  Google Scholar 

  39. Hollis ER 2nd, Jamshidi P, Lorenzana AO, Lee JK, Gray SJ, Samulski RJ, Zheng B, Tuszynski MH (2010) Transient demyelination increases the efficiency of retrograde AAV transduction. Mol Ther 18:1496–1500

    Article  PubMed  CAS  Google Scholar 

  40. Miller TM, Kaspar BK, Kops GJ, Yamanaka K, Christian LJ, Gage FH, Cleveland DW (2005) Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Ann Neurol 57:773–776

    Article  PubMed  CAS  Google Scholar 

  41. Towne C, Raoul C, Schneider BL, Aebischer P (2008) Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice. Mol Ther 16:1018–1025

    Article  PubMed  CAS  Google Scholar 

  42. Storek B, Reinhardt M, Wang C, Janssen WG, Harder NM, Banck MS, Morrison JH, Beutler AS (2008) Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain. Proc Natl Acad Sci USA 105: 1055–1060

    Article  PubMed  CAS  Google Scholar 

  43. Cearley CN, Vandenberghe LH, Parente MK, Carnish ER, Wilson JM, Wolfe JH (2008) Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Mol Ther 16:1710–1718

    Article  PubMed  CAS  Google Scholar 

  44. Lawlor PA, Bland RJ, Mouravlev A, Young D, During MJ (2009) Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates. Mol Ther 17: 1692–1702

    Article  PubMed  CAS  Google Scholar 

  45. Shevtsova Z, Malik JM, Michel U, Bahr M, Kugler S (2005) Promoters and serotypes: targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo. Exp Physiol 90:53–59

    Article  PubMed  CAS  Google Scholar 

  46. Kugler S, Lingor P, Scholl U, Zolotukhin S, Bahr M (2003) Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units. Virology 311:89–95

    Article  PubMed  CAS  Google Scholar 

  47. Brown BD, Gentner B, Cantore A, Colleoni S, Amendola M, Zingale A, Baccarini A, Lazzari G, Galli C, Naldini L (2007) Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol 25:1457–1467

    Article  PubMed  CAS  Google Scholar 

  48. Lock M, McGorray S, Auricchio A, Ayuso E, Beecham EJ, Blouin-Tavel V, Bosch F, Bose M, Byrne BJ, Caton T, Chiorini JA, Chtarto A, Clark KR, Conlon T, Darmon C, Doria M, Douar A, Flotte TR, Francis JD, Francois A, Giacca M, Korn MT, Korytov I, Leon X, Leuchs B, Lux G, Melas C, Mizukami H, Moullier P, Muller M, Ozawa K, Philipsberg T, Poulard K, Raupp C, Riviere C, Roosendaal SD, Samulski RJ, Soltys SM, Surosky R, Tenenbaum L, Thomas DL, van Montfort B, Veres G, Wright JF, Xu Y, Zelenaia O, Zentilin L, Snyder RO (2010) Characterization of a recombinant adeno-associated virus type 2 reference standard material. Hum Gene Ther 21:1273–1285

    Article  PubMed  CAS  Google Scholar 

  49. Rohr UP, Heyd F, Neukirchen J, Wulf MA, Queitsch I, Kroener-Lux G, Steidl U, Fenk R, Haas R, Kronenwett R (2005) Quantitative real-time PCR for titration of infectious recombinant AAV-2 particles. J Virol Methods 127:40–45

    Article  PubMed  CAS  Google Scholar 

  50. Aurnhammer C, Haase M, Muether N, Hausl M, Rauschhuber C, Huber I, Nitschko H, Busch U, Sing A, Ehrhardt A, Baiker A (2011) Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. Hum Gene Ther 23:18–28

    Google Scholar 

  51. Vandenberghe LH, Xiao R, Lock M, Lin J, Korn M, Wilson JM (2010) Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturing. Hum Gene Ther 21: 1251–1257

    Article  PubMed  CAS  Google Scholar 

  52. Zeltner N, Kohlbrenner E, Clement N, Weber T, Linden RM (2010) Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors. Gene Ther 17:872–879

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Elisabeth Dirren is supported by a fellowship from the Swiss Foundation for Research on Muscle Diseases (FSRMM). This work was also supported by the SMA Foundation and by the SystemsX.ch project “Neurochoice.” The authors thank Viviane Padrun and Fabienne Pidoux for their expert help in establishing protocols for AAV production.

Author information

Authors and Affiliations

  1. Brain Mind Institute, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland

    Elisabeth Dirren & Bernard L. Schneider

Authors
  1. Elisabeth Dirren
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bernard L. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institute of Experimental Neurology, San Raffaele Scientific Institute Division of Neuroscience, Milan, Italy

    Riccardo Brambilla

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Dirren, E., Schneider, B.L. (2014). Application of Viral Vectors to Motor Neuron Disorders. In: Brambilla, R. (eds) Viral Vector Approaches in Neurobiology and Brain Diseases. Neuromethods, vol 82. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-610-8_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-610-8_12

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-609-2

  • Online ISBN: 978-1-62703-610-8

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation